Vaxcyte, Inc.PCVXNASDAQ
Loading
R&D Expense Growth TrendStable
Percentile Rank63
3Y CAGR-16.9%
5Y CAGR+1.7%
Studio
Year-over-Year Change

Year-over-year research & development expense growth

3Y CAGR
-16.9%/yr
vs -3.8%/yr prior
5Y CAGR
+1.7%/yr
Recent deceleration
Acceleration
-13.1pp
Decelerating
Percentile
P63
Within normal range
vs 5Y Ago
1.1x
Modest growth
Streak
1 yr
Consecutive growthStable
PeriodValue
202566.65%
202443.42%
202396.13%
2022116.11%
20216.59%
202061.30%
201951.29%
2018135.78%
20170.00%